E2XE34 Stock Overview
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Exelixis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$99.40 |
| 52 Week High | US$99.40 |
| 52 Week Low | US$50.71 |
| Beta | 0.54 |
| 11 Month Change | 36.54% |
| 3 Month Change | 48.80% |
| 1 Year Change | 94.33% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 105.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| E2XE34 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | 27.2% | -1.1% | -0.6% |
| 1Y | 94.3% | 14.2% | 5.1% |
Return vs Industry: E2XE34 exceeded the BR Biotechs industry which returned 14.2% over the past year.
Return vs Market: E2XE34 exceeded the BR Market which returned 3.3% over the past year.
Price Volatility
| E2XE34 volatility | |
|---|---|
| E2XE34 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in BR Market | 9.1% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: E2XE34's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: Insufficient data to determine E2XE34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 1,310 | Mike Morrissey | www.exelixis.com |
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.
Exelixis, Inc. Fundamentals Summary
| E2XE34 fundamental statistics | |
|---|---|
| Market cap | R$56.36b |
| Earnings (TTM) | R$2.70b |
| Revenue (TTM) | R$12.04b |
21.0x
P/E Ratio4.7x
P/S RatioIs E2XE34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| E2XE34 income statement (TTM) | |
|---|---|
| Revenue | US$2.08b |
| Cost of Revenue | US$78.00m |
| Gross Profit | US$2.00b |
| Other Expenses | US$1.54b |
| Earnings | US$466.92m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.64 |
| Gross Margin | 96.25% |
| Net Profit Margin | 22.43% |
| Debt/Equity Ratio | 0% |
How did E2XE34 perform over the long term?
See historical performance and comparison